|
|
Post by mnholdem on Feb 25, 2015 13:51:25 GMT -5
Those are kevinmik's YMB posted notes from yesterday's earnings conference call. Either he also posted them at ST or somebody else copied them. Regardless, these bullet points are not related to today's RBC Health Conference (see thread header).
|
|
|
|
Post by kc on Feb 25, 2015 14:09:25 GMT -5
Thanks I corrected the posting to state that.
|
|
|
|
Post by seanismorris on Feb 25, 2015 14:52:13 GMT -5
My take away...
Afrezza production continues to ramp up, but demand can't be determined yet. Which is to be expected, the sales reps are just starting to pound the pavement. Word of mouth interest in Afrezza is strong (shown by demand for more sample packs) but Sanofi may have stalled Afrezzas launch a bit by not being prepared. Sanofi seems to have desired a soft launch with spending on marketing of Afrezza at the same time as Toujeo. Sanofi's focus was probably more on ensuring Toujeos success than Afrezzas, hopefully they've figured out Afrezza can be a stand alone success regardless.
The 12 unit timeline isn't really news, except it's taking longer than I'd expected. But it's more important for margins than Afrezza's adoption. Mannkind did say that it was just a matter of adding more powder, so their advances in putting more insulin in an equal volume isn't relevant yet. Switching to Sanofi's insulin and the corresponding trials may be a better time to introduce other changes. A pediatric Afrezza would be more appealing if less powder (concentrated product) was available. I don't see a need to change the inhaler for the pediatric market but hooking up a 9 volt battery to a device would not be that difficult..it would be considerably more expensive.
I'd rather hear more about what else is going on with the FDA. Is there a study with Toujeo + Afrezza? Anything to optimize the label? Mannkind doesn't seem to be able to say much, and what they are saying is pretty obvious. The areas they are targeting, pain and oncology we already knew about. More color on oncology would have been nice...that's like saying I'm going to college to get an education. It's a really broad area.
I hope they got more from the report regarding Technospheres opportunities than that... Mannkind seemed to be saying that they will be using existing meds. (probably off patent) to target these areas first... It doesn't sound like they are advancing the Torrey Pines efforts immediately. Generating cash flow, using known risk factors seems to come before a mega blockbuster. I hope it remains in the 5-10 year plan. Which is prudent but not as exciting.
|
|
